ОСТРЫЙ МИЕЛОИДНЫЙ ЛЕЙКОЗ: СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ (обзор литературы)
https://doi.org/10.51523/2708-6011.2011-8-1-5
Аннотация
В статье дается краткий обзор современных тенденций в лечении острого миелоидного лейкоза. Особое внимание уделяется определению факторов риска в дебюте заболевания и проведению риск-адаптированной терапии лейкозов.
Об авторах
И. Ю. Лендина
Республиканский научно-практический центр радиационной медицины и экологии человека
Беларусь
Беларусь
В. А. Змачинский
Белорусская медицинская академия последипломного образования
Беларусь
Беларусь
Д. Г. Цвирко
Республиканский научно-практический центр гематологии и трансфузиологии
Беларусь
Беларусь
А. Л. Усс
9-я Городская клиническая больница
Беларусь
Беларусь
Список литературы
1. Age and acute myeloid leukemia / F. R. Appelbaum [et al.] // Blood. - 2006. - Vol. 107, № 9. - P. 3481-3485.
2. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML, 10 trial. / D. Grimwade [et al.] // Blood. - 1998. - Vol. 92, № 7. - P. 2322-2333.
3. Mro´zek, K. Cytogenetics in acute leukaemia / K. Mro´zek, N. A. Heerema, C. D. Bloomfield // Blood Rev. - 2004. - Vol. 18, № 2. - P. 115-136.
4. Mro´zek, K. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances / K. Mro´zek, H. Do¨hner, C. D. Bloomfield // Curr Opin Hematol. - 2007. - Vol. 14, № 2. - P. 106-114.
5. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a Study of the AML Study Group Ulm / S. Frohling [et al.] // Blood. - 2002. - Vol. 100. - P. 4372-4380.
6. Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.
7. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations / H. Do¨hner [et al.] // Blood. - 2005. - Vol. 106, № 12. - P. 3740-3746.
8. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis / C. Thiede [et al.] // Blood. - 2002. - Vol. 99, № 12. - P. 4326-4335.
9. Favorable prognostic significance of CEBPAmutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) / C. Preudhomme [et al.] // Blood. - 2002. - Vol. 100, № 8. - P. 2717-2723.
10. Wenberg, L. B. Acute myeloid leukemia and acute promyelocytic leukaemia / L. B. Wenberg, J. D. Griffin, M. S. Tallman // Hematology Am Soc Hematol Educ Program. - 2003. - P. 82-101.
11. Aphase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study / W. R. Vogler [et al.] // J. Clin Oncol. - 1992. - Vol. 10, № 7. - P. 1103-1111.
12. Anthracycline dose intensification in acute myeloid leukemia / H. F. [et al.] // Fernandez N Engl J Med. - 2009. - Vol. 361. - P. 1249-1259.
13. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study / J. K. Weick [et al.] // Blood. - 1996. - Vol. 88, № 8. - P. 2841-2851.
14. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10) / I. M. Hann [et al.] // Blood. - 1997. - Vol. 89, № 7. - P. 2311-2318.
15. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations / F. R. Appelbaum [et al.] // Br J Haematol. - 2006. - Vol. 135. - P. 165-173.
16. Varying intensity of postremission therapy in acute myeloid leukaemia / P. A. Cassileth [et al.] // Blood. - 1992. - Vol. 79. - P. 1924-1930.
17. Intensive post-remission chemotherapy in adults with acute myeloid leukemia / R. J. Mayer [et al.] // N Engl J Med. - 1994. - Vol. 331, № 14. - P. 896-903.
18. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.
19. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group / E. Elonen [et al.] // Leukemia. - 1998. - Vol. 12. - P. 1041-1048.
20. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group / B. Lowenberg [et al.] // J Clin Oncol. - 1998. - Vol. 16. - P. 872-881.
21. Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial / R. F. Schlenk [et al.] // Leukemia. - 2003. - Vol. 17, № 8. - P. 1521-1528.
22. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study / S. P. Whitman [et al.] // Blood. - 2007. - Vol. 109, № 12. - P. 5164-5167.
23. Graft-versus-leukemia reactions after bone marrow transplantation / M. M. Horowitz [et al.] // Blood. - 1990. - Vol. 75, № 3. - P. 555-562.
24. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identicalsibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? / J. J. Cornelissen [et al.] // Blood. - 2007. - Vol. 109, № 9. - P. 3658-3666.
25. Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358. - P. 1909-1918.
26. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461 / J. C. Byrd [et al.] // J Clin Oncol. - 2004. - Vol. 22, № 6. - P. 1087-1094.
27. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.
28. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials / J. Koreth [et al.] // JAMA. - 2009. - Vol. 301, № 22. - P. 2349-2361.
29. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.
Рецензия
Для цитирования:
Лендина И.Ю., Змачинский В.А., Цвирко Д.Г., Усс А.Л. ОСТРЫЙ МИЕЛОИДНЫЙ ЛЕЙКОЗ: СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ (обзор литературы). Проблемы здоровья и экологии. 2011;(1):29-34. https://doi.org/10.51523/2708-6011.2011-8-1-5
For citation:
Lendina I.Yu., Zmachinskiy V.A., Tsvirko D.G., Uss A.L. ACUTE MYELOID LEUKEMIA: CURRENT APPROACHES TO DIAGNOSIS AND TREATMENT (literature review). Health and Ecology Issues. 2011;(1):29-34. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-1-5
Просмотров: 226
Послать статью по эл. почте 